Successful hepatitis C virus (HCV) therapy depends on effective pathways of care.
it. This requires taking responsibility for a defined region and all the HCV infection within that region, irrespective of how and by whom the virus was contracted.
Recent estimates suggest that around 215 000 are chronically infected with hepatitis C in the UK, and it is estimated that over 90% of cases are related to injecting drug use. 3 The majority who are referred to the specialist hepatitis services will be past or present drug users.
People who inject drugs (PWIDs) are thought to be a particularly difficult population to reach as they may have difficulty accessing and using traditional medical services.
Expert consensus suggests that increasing testing and uptake of services may be improved not just by the integration of diagnosis and treatment but also by integrated multidisciplinary care which also addresses the individuals' alcohol, drug use problems, social circumstances and general health simultaneously with their HCV specialist care. [4] [5] [6] [7] [8] [9] These concepts of care have not been rigorously tested in clinical trials, as they are system changes that cannot be randomized to individuals.
The Tayside region of Scotland has been a test bed for sequential development of integrated services over the last two decades, moving from standard secondary care-based hospital outpatients, onto nurse-supported treatment services, then to a HCV managed care network (MCN) 10, 11 and finally to a development in the MCN model which included a widespread dry blood spot testing programme in drug services and development in our outreach services across the region which included providing treatment within drug services and prisons.
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The aims of this study were to evaluate the outcomes of the individuals who had a positive hepatitis C antibody test in our region and to compare referral patterns, attendance and treatment outcomes over those four developmental stages, to investigate whether these changes translated into better clinical outcomes.
| METHODOLOGY
This is a cohort study of all adults who have received a positive hepatitis C antibody test in the geographical region of Tayside, Scotland.
The region has two cities, several major towns, a mixed urban and rural population with significant areas of deprivation and associated drug use. This is representative in microcosm of most developed health regions. This is an all-inclusive population-based study of the performance of a healthcare system for the diagnosis and treatment of HCV. Patients were followed up in or out of service from first diagnosis until SVR, death or moving residence outside the region.
Individuals were divided into four subgroups. T A B L E 1 Outcome of new diagnosis of HCV in the area. The majority of individuals (81.7%) had a history of injecting drug use, and 191 (6.2%) did not disclose any known risk factors. Table 1 lists further data for each subgroup.
The first phase of analysis was based on all antibody-positive individuals in each of the four subgroups; endpoints in this phase of the analysis were spontaneously resolving infection (651), dying before accessing care (324), moving from the region before accessing care (294) or unable to be traced (23). The high number moving out of the region before accessing care is a reflection of the three prisons in the area. They were not followed up from the point they moved out with the region. In addition, there were a number of individuals who had died before accessing care; this number was particularly high in the first two subgroups.
| Phase 2 analysis: HCV PCR positive or unknown analysis
The second phase of the study included 1830 individuals who were HCV PCR positive or HCV PCR status was unknown, who were living in our region (i.e. the target population for any treatment programme). The aim was to compare referral, attendance and treatment outcomes in each subgroup to determine whether changes to practice had a significant impact on outcomes. This is presented as cumulative data, time periods from referral to access to care and treatment.
Across the subgroups, 1786 (97.5%) were referred to our spe- Table 2 . In this analysis, it is difficult to break this down by treatment genotype, duration and regimen because an individual may be diagnosed in one time period and has been treated at a much later stage. SVRs for first treatments are between 61.6% and 77.4%
across the study. 
| Deaths in the subgroups
Within the study, there were 570 recorded deaths, and 69 of deaths were in individuals who were HCV PCR negative. Two hundred and eighty-four died before being able to access specialist HCV care. A significant number in this group died from drug-related deaths, HIVrelated illnesses or liver and hepatocellular carcinoma-related deaths.
The majority with HIV-related illness died before 2004. Of the 196 who died after accessing care, a significant number had liver cirrhosis and liver cancer. (Table 3) .
In all groups, many died from other serious illnesses not related to the liver, and the main cause of death was heart disease (30%), lung disease (19%) and cerebrovascular disease (13%).
When the rates of death between the four subgroups are viewed, there is an apparent reduction in death as the pathways change with the most recent subgroup having the lowest death rate (Table 4) .
Clearly, there are several cofounders for such an observation.
To The length of follow-up for the four subgroups is different. Within the same length of follow-up period (0-7 years), the latest subgroup (subgroup D) has significantly higher survival probability (i.e. lower risk of death) than the other three subgroups. We can further investigate the difference by employing Cox regression models (Table 5 ).
This further analysis of the time to all-cause mortality includes potential confounding risk factors which are age at first test (continuous variable), gender (male vs female), subgroup (A to D), HIV co-infection (yes or no) and SVR status (yes or no). The Cox proportional hazard model 14 is used to investigate whether the time to mortality is still significantly different among the four subgroups after adjusting for age at first test, gender, HIV co-infection and SVR.
T A B L E 2 Final outcomes of HCV PCR positive individuals

Caseload total (1830)
Subgroup A n=292
Subgroup B n=324
Subgroup C n=393
Subgroup D n=821
Total referred (1786) The SVR data are based across genotypes and using various treatment regimens and include individuals who were on clinical trials in our area. c Sixteen patients had not completed treatment by end of study. Mental and behavioural disorders due to alcohol dependence syndrome 8 5 1
Not known 7 11 8
Other cancer not liver related 7 14 6
Other serious illness resulting in death 23 51 16
Other specified viral hepatitis without mention of hepatic coma 
T A B L E 3 Causes of death recorded in HCV-positive individuals
The SVR status does not satisfy the proportional hazard assumption; that is, the baseline hazards for patients with and without SVR are not the same. Therefore, a stratified analysis on SVR is performed to guarantee that the proportional hazard assumption is not violated.
The results are shown in the following table.
The hazard ratio of SVR is omitted as stratified Cox regression ignores the coefficient of the stratification factor, which is SVR in this model. We can see that after adjusting for age, gender, HIV infection and SVR, only the latest subgroup (D) has significantly reduced risk of death (HR=0.53, P<.001) comparing to the earliest subgroup (A).
| DISCUSSION
This study demonstrates that the referral and treatment pathway in
Tayside acts as a model of best practice in how a coordinated care network can ensure widened access to testing and treatment and significantly improve outcomes for a cohort that contains significant numbers who are often deemed ill-suited for hepatitis C treatment.
Improving diagnosis of HCV and access to care will only be effective if they are able to receive effective treatment and be cured of hepatitis C. All service developments were aimed at achieving successful SVRs. The greatest impact on our pathway was the introduction of routine dry blood spot testing (DBST) in drug services and community clinics and GP practices. This has significantly contributed to an increase in the number of new hepatitis C cases. In 2008, there were 127 new diagnosis (rate of 32.1 per 100 000 of our population) and the rate of new diagnosis increased to 68.5 per 100 000 which is higher than the overall rate for Scotland. Patients in subgroups A, B and C have had a much longer opportunity to be exposed to therapy and have also been exposed to the newer pathways of care, yet despite this bias against the newest pathway of care, it still demonstrates it is superior.
It is important to note that the developments in our service were not achieved by a large increase in our nursing and medical staff. Our service is mainly nurse led, and these outcomes have been achieved by 0.8 full-time equivalent (FTE) specialist nurse when the MCN was introduced and the addition of another FTE nurse when DBST was introduced. The aim of the network has always been to empower colleagues to be involved in BBV testing and follow-up, and the high referral and attendance rates have been achieved by healthcare professionals such as drug workers, GPs, prison nurses and social workers taking the opportunity to discuss referral and treatment. Good communication and easy access to specialist service are important. There is a perception that individuals with hepatitis C can be "difficult to reach"; however, our centre has found that this is not the case. We are always aware that it might be more likely that our services are "difficult to find" and our service redesign was aimed at providing services in the right time and place. These data have also been used to assist with local projects carried out with general practitioners and community pharmacists which have been shown to increase the numbers tested and accessing care.
The most striking finding from the study has been the greater than 40% reduction in risk of death in the first subgroup compared to the most recent. Intuitively, the older age of the earlier subgroup and poorer HIV infection outcomes of that time would have been thought to explain this; however, multivariate analysis shows this survival benefit is maintained even when SVR, HIV status and age are taken into account.
In our cohort, the dominant causes of death are drug related, trauma and suicide, all strongly associated with active drug use. In our final subgroup, the care pathway has led to massive increase in testing and diagnosis of HCV infection, and this would have been expected to lead to an increased risk of death and yet we have observed the reverse.
The associated increased speed of access into care and focus on HCV treatment may have led to a greater degree of engagement with health services and may have had a stabilizing effect on drug-using behaviour.
This is an observational cohort study so the power to ascribe causality between the interventions described and the outcomes is limited to describing associations. However, it is very difficult to test the system change and complex interventions undertaken here in a randomized trial, without expensive and large cluster randomized trials, which are probably impossible to perform.
| CONCLUSION
In the field of HCV treatment, much has been made of the waterfall of care with loss of large numbers of patients from the care pathway at each stage. In this study, we report the outcomes of a series of changes to the care pathway, with modest investment in infrastructure but integration of existing services to work smarter. This has led to 97.5% of our HCV caseload being referred to our specialist services with 89% attending at least one clinic appointment for assessment.
Over the course of the study with the introduction of new pathways, the number who accessed specialist care within a year of diagnosis significantly increased from around 26.3% to 72.9%. There was a significant decrease in the time period from diagnosis to SVR.
At the end of the study, 78% of estimated HCV cases had been diagnosed and 40% of the total caseload had an SVR. Our data show that involving colleagues within a network can significantly increase HCV testing, diagnosis and treatment and can bring patients who are perceived as difficult to reach into care. Additionally, the entry into HCV care of those traditionally thought unsuitable is associated with reduced risk of death. 
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